Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer

Lenvatinib is a small oral molecule able to inhibit three of the extracellular and intracellular molecules involved in the modulation of angiogenesis and lymphangiogenesis: vascular endothelial growth factor receptor 1–3, fibroblast growth factor receptor 1–4, and platelet-derived growth factor rece...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Onco Targets Ther
Hlavní autoři: Lorusso, Loredana, Pieruzzi, Letizia, Biagini, Agnese, Sabini, Elena, Valerio, Laura, Giani, Carlotta, Passannanti, Paolo, Pontillo-Contillo, Benedetta, Battaglia, Valentina, Mazzeo, Salvatore, Molinaro, Eleonora, Elisei, Rossella
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2016
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5079697/
https://ncbi.nlm.nih.gov/pubmed/27799794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S84625
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky